Filter Results
:
(1,001)
Show Results For
-
All HBS Web
(1,001)
- People (4)
- News (249)
- Research (603)
- Events (7)
- Multimedia (24)
- Faculty Publications (389)
Show Results For
-
All HBS Web
(1,001)
- People (4)
- News (249)
- Research (603)
- Events (7)
- Multimedia (24)
- Faculty Publications (389)
- 06 Nov 2019
- Video
Accelerating Your Career With Business and Science
- August 2008 (Revised September 2008)
- Case
The Flaxil Label (B)
This case focuses on the 2001 negotiation between Mytex Pharmaceuticals and the U.S. Food and Drug Administration (FDA). The outcome of the negotiation would determine the new label for Mytex's blockbuster drug for arthritis, Flaxil. The negotiation is quite...
View Details
Keywords:
Governance;
Risk and Uncertainty;
Value Creation;
Negotiation;
Attitudes;
Health Care and Treatment;
Government Administration;
Pharmaceutical Industry;
United States
Barron, Greg M. "The Flaxil Label (B)." Harvard Business School Case 909-002, August 2008. (Revised September 2008.)
- September 2021 (Revised October 2022)
- Supplement
Hester Pharmaceuticals (B): Securing Supply
By: Dante Roscini and John Masko
Supplements the (A) case. In late 2020, demand for Hester Pharmaceutical’s (Hester’s) breakthrough oncology drug Akrozumab was outstripping the company’s most optimistic projections. In order to increase manufacturing capacity and meet the demand, Hester was...
View Details
Keywords:
COVID-19 Pandemic;
Cost vs Benefits;
Trade;
Supply Chain;
Global Strategy;
Buildings and Facilities;
Operations;
Health Care and Treatment;
Demand and Consumers;
Global Range;
Globalized Markets and Industries;
Pharmaceutical Industry;
Italy;
China;
United States;
Germany
Roscini, Dante, and John Masko. "Hester Pharmaceuticals (B): Securing Supply." Harvard Business School Supplement 722-009, September 2021. (Revised October 2022.)
- June 1999 (Revised June 2000)
- Case
Eckerd Corporation
By: Michael E. Porter and John E. Kelleher
Describes the history and current situation in the retail pharmacy industry, including competition from new merchants and Internet drugstores. Eckerd, one of the top four drug chains, must decide how to position itself for the future.
View Details
Porter, Michael E., and John E. Kelleher. "Eckerd Corporation." Harvard Business School Case 799-141, June 1999. (Revised June 2000.)
- Video
Dr. Yusuf Hamied
Dr. Yusuf Hamied, Chair of the pioneering Indian generic drugs company Cipla, discusses the timeline and strategies that allowed him to bring affordable HIV/AIDS treatments to market.
View Details
- July 2008 (Revised September 2008)
- Case
Recent Developments in the Ranbaxy Case
By: Robert C. Pozen
This brief case describes settlements Indian drug maker Ranbaxy has made with Pfizer and AstraZeneca, as well as Daiichi Kangyo's purchase of a majority shareholding in Ranbaxy in 2008.
View Details
Keywords:
Mergers and Acquisitions;
Patents;
Lawsuits and Litigation;
Ownership Stake;
Pharmaceutical Industry;
India
Pozen, Robert C. "Recent Developments in the Ranbaxy Case." Harvard Business School Case 609-010, July 2008. (Revised September 2008.)
- 01 Oct 2019
- News
The bias that can cause catastrophe
- 04 Sep 2018
- First Look
New Research and Ideas, September 4, 2018
'Wonder Drug' That Killed Babies In the early 1960s, a popular drug taken by patients worldwide for a range of maladies was found to cause severe birth defects and other health problems in babies born to mothers who had taken it during a...
View Details
Keywords:
Dina Gerdeman
- October 2006 (Revised August 2007)
- Case
Calloway Laboratory: Pee for Profit
By: Richard G. Hamermesh and David Kiron
Describes the formation and rapid growth of a drug-testing company. The company needs to decide whether to enter the painkiller testing market, in addition to growing its drug treatment center business.
View Details
Keywords:
For-Profit Firms;
Health Care and Treatment;
Health Testing and Trials;
Growth and Development Strategy;
Market Entry and Exit;
Health Industry
Hamermesh, Richard G., and David Kiron. "Calloway Laboratory: Pee for Profit." Harvard Business School Case 807-040, October 2006. (Revised August 2007.)
- September 2020
- Case
Minerva 2004: Discovery
By: John R. Wells and Benjamin Weinstock
After nearly five years in operation, Doctor Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), was reflecting on the company’s next steps. In a few short years, she and her small team had managed to develop a nanoparticle process for...
View Details
Keywords:
Entrepreneurship;
Financing and Loans;
Strategy;
Decision Choices and Conditions;
Biotechnology Industry
Wells, John R., and Benjamin Weinstock. "Minerva 2004: Discovery." Harvard Business School Case 721-389, September 2020.
- May 2021
- Case
The SMA Foundation: Steering Therapeutic Research and Development in a Rare Disease
By: Amitabh Chandra, Spencer Lee-Rey and Caroline Marra
This case explores incentives for rare disease drug development by chronicling the role of the Spinal Muscular Atrophy (SMA) Foundation in forming strategic partnerships with the scientific research community and pharmaceutical developers to transform the trajectory...
View Details
Keywords:
Innovation and Invention;
Strategy;
Business or Company Management;
Society;
Health;
Public Administration Industry;
Health Industry;
United States
Chandra, Amitabh, Spencer Lee-Rey, and Caroline Marra. "The SMA Foundation: Steering Therapeutic Research and Development in a Rare Disease." Harvard Business School Case 621-112, May 2021.
- November 2010
- Supplement
Hikma Pharmaceuticals (B)
By: John A. Quelch
By 2009, Hikma Pharmaceuticals operated 13 manufacturing plants in 8 countries of which 5 were approved by the U.S. Food and Drug Administration. Hikma tracked its sales revenues over the period to show where the largest contributors were from.
View Details
Quelch, John A. "Hikma Pharmaceuticals (B)." Harvard Business School Supplement 511-075, November 2010.
- March 1993
- Supplement
Burroughs Wellcome and AZT (B)
Describes Burroughs Wellcome's response to protests over the pricing of its AIDS drug AZT in September 1989. Also presents short-term reactions by government officials, AIDS activists, and investors to Burroughs Wellcome's strategy.
View Details
Keywords:
Ethics;
Health Pandemics;
Multinational Firms and Management;
Price;
Crime and Corruption;
Risk and Uncertainty;
Business Strategy;
Business and Community Relations;
Business and Government Relations;
Business and Shareholder Relations;
Pharmaceutical Industry
Emmons, Willis M., III. "Burroughs Wellcome and AZT (B)." Harvard Business School Supplement 793-114, March 1993.
- 29 Oct 2015
- News
Options to Promote Competitive Generics Markets in the United States
- 07 Dec 2010
- First Look
First Look: Dec. 7
case:http://cb.hbsp.harvard.edu/cb/product/711417-PDF-ENG Plavix: Drugs in the Age of Personalized Medicine Richard G. Hamermesh, Mara G. Aspinall, and Rachel GordonHarvard Business School Note 811-001 PIavix, one of the world's best...
View Details
Keywords:
Sean Silverthorne
- January 2009
- Case
When Supply is of Public Interest: Roche & Tamiflu
The case focuses on the challenges of Roche maintaining a supply network for a global influenza pandemic response initiative based on its antiviral drug Tamiflu. The Roche group is a 40 billion CHF company consisting of a pharmaceutical division and a diagnostic...
View Details
Keywords:
Global Strategy;
Health Pandemics;
Distribution;
Logistics;
Production;
Supply Chain Management;
Performance Capacity;
Pharmaceutical Industry
Watson, Noel H., Laura Rock Kopczak, and Prashant Yadav. "When Supply is of Public Interest: Roche & Tamiflu." Harvard Business School Case 609-061, January 2009.
- 23 Jun 2015
- Video
Innovations Wanted: Beating Brain Disease
- Awards
Edward Kremers Award of the American Institute of the History of Pharmacy
Winner of the 2006 Edward Kremers Award from the American Institute of the History of Pharmacy for best book published in the previous two years for Pharmacopolitics: Drug Regulation in the United States and Germany (The University of North Carolina Press,...
View Details
- 22 Feb 2016
- News
The ‘Mother of Fair Trade’ was an Unabashed Price Protectionist
- Research Summary
Overview
By: John Beshears
In his research, Professor Beshears shows how managers can influence the behavior of customers and employees by changing the decision-making environment to call attention to a decision, to use psychological framing to shape assessments of options, or to help...
View Details